Literature DB >> 21330240

Risk-benefit trade-offs in revascularisation choices.

Jerome J Federspiel1, Sally C Stearns, Ron T van Domburg, Brett C Sheridan, Jennifer L Lund, Patrick W Serruys.   

Abstract

AIMS: When patients choose percutaneous coronary intervention (PCI) over coronary artery bypass grafting (CABG), they accept an increased long-term risk of repeat revascularisation in exchange for short-term morbidity benefits. This paper quantifies the risk-benefit trade-off faced by patients with multiple vessel coronary artery disease. METHODS AND
RESULTS: Data from the Arterial Revascularisation Therapies Study are used to generate risk-benefit acceptability curves for PCI versus CABG. Risks are measured by the long-term likelihood of repeat revascularisation while benefits are measured by short-term reductions in pain or improvements in health-related quality of life (HRQL). PCI patients faced a risk of 0.81 additional revascularisation events over three years in exchange for being pain-free at one month. A patient would need to be willing to tolerate a risk of 1.06 additional revascularisation events at three years, in exchange for being pain free at one month to be 95% confident that choosing PCI over CABG is risk-effective for him/her.
CONCLUSIONS: The risk-benefit framework outlined in this study provides information to enable physicians to help their patients weigh directly each procedure's risks and benefits. While trade-offs are typically measured in quality-adjusted life years, using pain reduction to reflect benefits may provide a more tangible framework for patients.

Entities:  

Mesh:

Year:  2011        PMID: 21330240      PMCID: PMC3061312          DOI: 10.4244/EIJV6I8A163

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  22 in total

1.  Analysis of trends in coronary artery bypass grafting and percutaneous coronary intervention rates in Washington state from 1987 to 2001.

Authors:  Matthew R Ulrich; Douglas M Brock; Andrew A Ziskind
Journal:  Am J Cardiol       Date:  2003-10-01       Impact factor: 2.778

2.  A single European currency for EQ-5D health states. Results from a six-country study.

Authors:  Wolfgang Greiner; Tom Weijnen; Martin Nieuwenhuizen; Siem Oppe; Xavier Badia; Jan Busschbach; Martin Buxton; Paul Dolan; Paul Kind; Paul Krabbe; Arto Ohinmaa; David Parkin; Montserat Roset; Harri Sintonen; Aki Tsuchiya; Frank de Charro
Journal:  Eur J Health Econ       Date:  2003-09

3.  Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial.

Authors:  Patrick W Serruys; Andrew T L Ong; Lex A van Herwerden; J Eduardo Sousa; Adib Jatene; Johannes J R M Bonnier; Jacques P M A Schönberger; Nigel Buller; Robert Bonser; Clemens Disco; Bianca Backx; Paul G Hugenholtz; Brian G Firth; Felix Unger
Journal:  J Am Coll Cardiol       Date:  2005-08-16       Impact factor: 24.094

4.  Moderators of treatment outcomes: clinical, research, and policy importance.

Authors:  Helena C Kraemer; Ellen Frank; David J Kupfer
Journal:  JAMA       Date:  2006-09-13       Impact factor: 56.272

5.  Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation.

Authors:  R I Horwitz; B H Singer; R W Makuch; C M Viscoli
Journal:  J Clin Epidemiol       Date:  1996-04       Impact factor: 6.437

6.  Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease.

Authors:  Edward L Hannan; Chuntao Wu; Gary Walford; Alfred T Culliford; Jeffrey P Gold; Craig R Smith; Robert S D Higgins; Russell E Carlson; Robert H Jones
Journal:  N Engl J Med       Date:  2008-01-24       Impact factor: 91.245

7.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.

Authors:  Patrick W Serruys; Marie-Claude Morice; A Pieter Kappetein; Antonio Colombo; David R Holmes; Michael J Mack; Elisabeth Ståhle; Ted E Feldman; Marcel van den Brand; Eric J Bass; Nic Van Dyck; Katrin Leadley; Keith D Dawkins; Friedrich W Mohr
Journal:  N Engl J Med       Date:  2009-02-18       Impact factor: 91.245

8.  Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease.

Authors:  Victor M G Legrand; Patrick W Serruys; Felix Unger; Ben A van Hout; Mathias C M Vrolix; Geert M P Fransen; Torsten Toftegaard Nielsen; Peter Kildeberg Paulsen; Ricardo Seabra Gomes; João M G de Queiroz e Melo; José P Marques dos Santos Neves; Wietze Lindeboom; Bianca Backx
Journal:  Circulation       Date:  2004-03-01       Impact factor: 29.690

9.  Short- and long- term health related quality-of-life and anginal status after randomisation to coronary stenting versus bypass surgery for the treatment of multivessel disease: results of the Arterial Revascularisation Therapy Study (ARTS).

Authors:  Ron T van Domburg; Joost Daemen; Susanne S Pedersen; Marco Bressers; Lex A van Herwerden; Brian G Firth; Felix Unger; Patrick W Serruys
Journal:  EuroIntervention       Date:  2008-01       Impact factor: 6.534

10.  Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions.

Authors:  Elisabeth Fenwick; Bernie J O'Brien; Andrew Briggs
Journal:  Health Econ       Date:  2004-05       Impact factor: 3.046

View more
  2 in total

Review 1.  Revascularization in multivessel CAD: a functional approach.

Authors:  Joanne Shannon; Antonio Colombo
Journal:  Nat Rev Cardiol       Date:  2012-01-31       Impact factor: 32.419

2.  Global Risk Score and Clinical SYNTAX Score as Predictors of Clinical Outcomes of Patients Undergoing Unprotected Left Main Percutaneous Catheter Intervention.

Authors:  Lucky Cuenza; Marianne P Collado; James Ho Khe Sui
Journal:  Cardiol Res       Date:  2017-12-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.